What is MASLD?

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the current name for fatty liver disease associated with at least one cardiometabolic risk factor, such as overweight, type 2 diabetes, high blood pressure or abnormal blood fats, after other important causes of liver fat are considered. It was previously called non-alcoholic fatty liver disease (NAFLD). Some people develop liver inflammation and injury, called MASH; a smaller proportion progress to advanced scarring (fibrosis) or cirrhosis.

What causes fatty liver, and who is at risk?

MASLD is closely linked with insulin resistance and metabolic health. Risk is higher with abdominal overweight or obesity, type 2 diabetes or prediabetes, high triglycerides or abnormal cholesterol, high blood pressure, sleep apnoea and low physical activity. Risk can occur at a lower body weight in South Asian people, so appearance alone cannot exclude it.

Alcohol, viral hepatitis, some medicines and less common genetic or metabolic disorders can also cause liver fat or injury. Tell your clinician honestly about alcohol, prescribed medicines, supplements and family history so the correct cause is assessed.

What are the symptoms of MASLD?

Most people have no clear symptoms, particularly in early disease. Fatty liver may be found after an ultrasound or abnormal liver blood tests. Some people report tiredness or a dull discomfort in the right upper abdomen, but these symptoms are not specific and need proper evaluation.

Yellow eyes or skin, abdominal swelling, vomiting blood, black stools, confusion or unusual drowsiness can indicate serious liver disease and require urgent medical care.

How is fatty liver diagnosed?

Diagnosis begins with medical history, examination and tests chosen for the individual. Blood tests may include ALT, AST, platelet count, bilirubin, albumin, glucose or HbA1c and a lipid profile. Tests for hepatitis or other causes may be needed. Normal ALT or AST does not reliably exclude significant fibrosis.

Ultrasound can detect liver fat but cannot accurately stage inflammation or fibrosis and may miss mild steatosis. A clinician may use transient elastography (FibroScan) or another validated non-invasive test when fibrosis risk needs clarification. Liver biopsy is not required for everyone; specialists reserve it for selected cases where diagnosis or staging remains uncertain.

What is FIB-4, and why does fibrosis assessment matter?

FIB-4 is a first-line risk-stratification calculation based on age, AST, ALT and platelet count. It estimates the likelihood of advanced fibrosis; it does not diagnose fibrosis or replace medical assessment. A low result can help identify many lower-risk adults, while an indeterminate or high result usually leads to a second assessment such as elastography or a specialist blood test.

Common pathways use 1.3 as the lower-risk threshold for adults aged 35–65 and 2.0 for adults older than 65. Results at or above the age-appropriate threshold usually lead to secondary assessment. Accuracy is limited in adults under 35 and during acute illness. Do not interpret a calculator result alone—your clinician must consider age, laboratory ranges, other diseases and the full clinical picture.

How is MASLD treated?

Treatment aims to reduce liver injury and cardiovascular risk. The foundation is a sustainable eating pattern, regular movement, gradual weight management where appropriate, adequate sleep and management of diabetes, blood pressure and cholesterol. A Mediterranean-style pattern—vegetables, fruit in sensible portions, whole grains, pulses, nuts, fish and unsaturated fats—can be adapted to Indian meals. Limit sugary drinks, excess refined carbohydrates, highly processed foods and excess saturated fat.

Aim for at least 150 minutes of moderate physical activity each week if medically suitable, plus muscle-strengthening activity. Begin gradually if inactive or if heart, joint or other medical problems are present. Even modest weight loss can reduce liver fat; larger sustained loss may be needed to improve inflammation and fibrosis. Avoid crash diets.

There is no single medicine suitable for every person with MASLD. Clinicians may prescribe medicines for diabetes, obesity, cholesterol or other conditions based on individual indications. Liver-directed treatment may be considered by a specialist for selected patients with confirmed significant fibrosis. Do not use “liver detox” products, herbal mixtures, high-dose vitamins or prescription medicines without advice; some can injure the liver.

Can MASLD be prevented or monitored?

Maintain regular physical activity, a balanced eating pattern and a healthy waist and weight for you. Check blood pressure, glucose and lipids as advised. Avoid smoking and discuss alcohol with your clinician—people with clinically significant fibrosis (F2 or higher) should completely abstain from alcohol. If MASLD is diagnosed, follow-up frequency depends on metabolic risks and fibrosis assessment; repeat blood tests or fibrosis evaluation may be recommended rather than repeated ultrasound alone.

Frequently asked questions

Is MASLD the same as NAFLD?

MASLD is the newer name and definition for metabolic fatty liver disease. Your older reports may still use NAFLD.

Can a thin person have fatty liver?

Yes. Metabolic risks and genetics matter, and South Asian people may develop MASLD at a lower BMI.

Does a normal liver test rule it out?

No. Liver enzymes can be normal despite fatty liver or fibrosis.

Is ultrasound enough to assess scarring?

No. Ultrasound detects fat but does not reliably stage fibrosis; FIB-4 and elastography may be used.

Can fatty liver improve?

Liver fat and inflammation often improve when metabolic risks are managed, but advanced fibrosis requires ongoing care.

Should I take a liver tonic?

No product should be started without medical advice. Supplements can interact with medicines or harm the liver.

Medical sources

Medical review

Medical review pending. This draft has not yet been approved by Dr. Ajay T. Parmar. Reviewer attribution and a medical-review date should be added only after documented approval.

Published 9 November 2026. This page provides patient education and does not issue an individual diagnosis or prescription.

Need advice about a fatty-liver report?

Request a General Medicine consultation at Lotus Hospital, Krishnanagar, Ahmedabad. Appointments are confirmed manually by phone or WhatsApp.

Book AppointmentWhatsApp

Medical disclaimer: This article is for general information and patient education. It does not replace consultation, examination, diagnosis or an individual treatment plan. Do not wait for a website or WhatsApp reply during urgent symptoms.